Zobrazeno 1 - 9
of 9
pro vyhledávání: '"329"'
Autor:
Romain Guieze, Anne Calleja, Loic Ysebaert, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Fontanet Bijou, Anne Quinquenel, Annie Brion, Kamel Laribi
Publikováno v:
61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Ibrutinib has revolutionized the management of RR CLL in the past 5 years, improving overall survival (OS) over standard chemo-immunotherapies (CIT) in the registration trials HELIOS and RESONATE. Recently, based on these two studies, a score has bee
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Autor:
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Christopher R. Flowers, Jeffrey M. Switchenko
Publikováno v:
Blood. 134:3416-3416
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease. Patients exhibit a 30%-40% relapse/refractory rate on standard first-line therapy and are known to have poor outcomes with relapsed/refractory disease, indicating a
Publikováno v:
Blood. 132:4979-4979
Background Although significant advances have been made over the past 10 years in the treatment of Immune Thrombocytopenia (ITP), challenges remain in addressing the burden of disease and unmet needs of patients. In rare diseases especially, natural
Autor:
Yuan-Shung Huang, Brian T. Fisher, Richard Aplenc, Karen R. Rabin, Kelly D. Getz, Jennifer J. Wilkes, Viviane C. Cahen, Yimei Li, Lena E. Winestone, Amanda M. DiNofia, M. Monica Gramatges, Alix E. Seif, Caitlin W Elgarten
Publikováno v:
Blood. 132:624-624
Administrative databases can be used to study outcomes including patients outside of clinical trials and have been used to identify relapse and HSCT in adult and adolescent/young adult leukemia populations. However, there are no published studies usi
Autor:
Jennifer S. Temel, Tanya Keenan, Yi-Bin Chen, Harry VanDusen, Areej El-Jawahri, Daniel J. DeAngelo, Amir T. Fathi, Thomas W. LeBlanc, Philip C. Amrein, David P. Steensma, Lara Traeger, Richard Stone, Karen K. Ballen, Martha Wadleigh, Gregory A. Abel, Gabriela S. Hobbs
Publikováno v:
Blood. 126:2104-2104
Introduction: Older adults (≥ 60 years) with acute myeloid leukemia (AML) generally have a poor prognosis and a high rate of health care utilization including intensive care unit (ICU) admissions. While the outcomes of older patients with advanced
Autor:
Shaji Kumar, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, David S. Siegel, Keith Stewart, Martin H. van Vliet, Kenneth C. Anderson, Andrzej Jakubowiak, Donna E. Reece, Sundar Jagannath, Ravi Vij, Rafael Fonseca, Erik H. van Beers, Todd M. Zimmerman, Joan Levy, Ajai Chari, Daniel Lebovic
Publikováno v:
Blood. 122:1854-1854
Introduction Multiple Myeloma is not a single disease. There is increasing support for risk classification in combination with treatment decision making because of its impact on clinical outcomes. Here we demonstrate additional evidence of the progno
Autor:
Matthew B. Siegel, Patrick J. Stiff, Aileen Go, Tulio E. Rodriguez, Brian Hess, Maria Theodorou, Michael Tallarico, Shams Bakhos, Scott E. Smith
Publikováno v:
Blood. 120:3102-3102
Abstract 3102 Identifying the optimal patients and timing for allogeneic hematopoietic stem cell transplant (HSCT) is an ongoing challenge for transplant centers that requires assessment of more than just the disease status and stage. Pre-existing co
Autor:
Ursula Haak, Rita Pasold, Sabine Hahnfels, Thomas-Hein Ittel, Christian Klinkenstein, Sabine Neser, Andreas Neubauer, Franz-Adolph Hoffmann, Ullrich von Gruenhagen, Ullrich Mey, Klaus Dachselt, Dorothee Bleyl, Mathias Freund, Ralph Naumann, Klaus Hieke, Heiner Wolf, Erika Kettner, Thomas Fietz, Volker Lakner, Helga Schwenke, Gottfried Doelken, Detlev Haehling, Henning Eschenburg, Klaus Hoeffken, Michael Assmann, Dietger Niederwieser, Michael Herold, Astrid Franke, Norbert Grobe, Robert Rohrberg, Michael R. Clemens, H.-H. Wolf, Peter Richter
Publikováno v:
Blood. 104:87-87
Background: Clinical superiority of R-MCP (rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP alone in patients with advanced stage indolent Non-Hodgkin’s-Lymphoma was demonstrated in a prospective, randomized, controlled, multicenter cli